Arnold Lentnek

4.2k total citations · 2 hit papers
36 papers, 3.3k citations indexed

About

Arnold Lentnek is a scholar working on Epidemiology, Infectious Diseases and Pharmacology. According to data from OpenAlex, Arnold Lentnek has authored 36 papers receiving a total of 3.3k indexed citations (citations by other indexed papers that have themselves been cited), including 22 papers in Epidemiology, 18 papers in Infectious Diseases and 10 papers in Pharmacology. Recurrent topics in Arnold Lentnek's work include Antibiotics Pharmacokinetics and Efficacy (9 papers), Pneumonia and Respiratory Infections (8 papers) and Antimicrobial Resistance in Staphylococcus (8 papers). Arnold Lentnek is often cited by papers focused on Antibiotics Pharmacokinetics and Efficacy (9 papers), Pneumonia and Respiratory Infections (8 papers) and Antimicrobial Resistance in Staphylococcus (8 papers). Arnold Lentnek collaborates with scholars based in United States, Canada and Argentina. Arnold Lentnek's co-authors include Thomas Louie, Mark A. Miller, Kathleen M. Mullane, Yoav Golan, Karl Heinz Weiss, Rob Roy MacGregor, Sherwood L. Gorbach, Youe‐Kong Shue, P.S. Sears and G. Ralph Corey and has published in prestigious journals such as New England Journal of Medicine, Journal of Clinical Investigation and Gastroenterology.

In The Last Decade

Arnold Lentnek

35 papers receiving 3.1k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Fidaxomicin versus Vancomycin for Clostridium difficile Infection

2011 1.1k citations Thomas Louie, Mark A. Miller et al. New England Journal of Medicine profile →
Inhibition of Granulocyte Adherence by Ethanol, Prednisone, and Aspirin, Measured with an Assay System

1974 398 citations Arnold Lentnek et al. New England Journal of Medicine profile →

Peers

Countries citing papers authored by Arnold Lentnek

Since Specialization

Citations

This map shows the geographic impact of Arnold Lentnek's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Arnold Lentnek with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Arnold Lentnek more than expected).

Fields of papers citing papers by Arnold Lentnek

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Arnold Lentnek. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Arnold Lentnek. The network helps show where Arnold Lentnek may publish in the future.

Co-authorship network of co-authors of Arnold Lentnek

This figure shows the co-authorship network connecting the top 25 collaborators of Arnold Lentnek. A scholar is included among the top collaborators of Arnold Lentnek based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Arnold Lentnek. Arnold Lentnek is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study 2014 ·BMC Infectious Diseases ·Martín E. Stryjewski, Arnold Lentnek, William O’Riordan, John Pullman, Paul Anantharajah Tambyah, José M. Miró, Vance G. Fowler, Steven L. Barriere, Michael M. Kitt, G. Ralph Corey	56
2	Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy 2013 ·BMC Infectious Diseases ·Mark A. Miller, Thomas Louie, Kathleen M. Mullane, Karl Heinz Weiss, Arnold Lentnek, Yoav Golan, Yin Kean, (unknown)	116
3	Fidaxomicin versus Vancomycin for Clostridium difficile Infection breakdown → 2011 ·New England Journal of Medicine ·Thomas Louie, Mark A. Miller, Kathleen M. Mullane, Karl Heinz Weiss, Arnold Lentnek, Yoav Golan, Sherwood L. Gorbach, P.S. Sears, Youe‐Kong Shue	1146
4	Prevalence of beta-lactam nonsusceptible Gram-negative bacilli and use and interpretation of current susceptibility breakpoints: a survey of infectious disease physicians 2011 ·Diagnostic Microbiology and Infectious Disease ·Alexander J. Kallen, Susan E. Beekmann, Brandi Limbago, Arnold Lentnek, Philip M. Polgreen, Jean B. Patel, Arjun Srinivasan	9
5	Efficacy of Fidaxomicin Versus Vancomycin as Therapy for Clostridium difficile Infection in Individuals Taking Concomitant Antibiotics for Other Concurrent Infections 2011 ·Clinical Infectious Diseases ·Kathleen M. Mullane, Mark A. Miller, Karl Heinz Weiss, Arnold Lentnek, Yoav Golan, P.S. Sears, Youe‐Kong Shue, Thomas Louie, Sherwood L. Gorbach	181
6	Telavancin versus Vancomycin for Hospital-Acquired Pneumonia due to Gram-positive Pathogens 2010 ·Clinical Infectious Diseases ·Eric Rubinstein, Tahaniyat Lalani, G. Ralph Corey, Zeina A. Kanafani, Esteban C. Nannini, (unknown), Galia Rahav, Michael S. Niederman, Marin H. Kollef, Andrew F. Shorr, Phong Ching Lee, Arnold Lentnek, Carlos M. Luna, (unknown), Antoní Torres, Michael M. Kitt, (unknown), Steven L. Barriere, H. David Friedland, Martín E. Stryjewski, (unknown)	196
7	Voriconazole Use for Endemic Fungal Infections 2009 ·Antimicrobial Agents and Chemotherapy ·Alison G. Freifeld, Laurie A. Proia, David R. Andes, Larry M. Baddour, Janis E. Blair, Brad Spellberg, Sandra R. Arnold, Arnold Lentnek, L. Joseph Wheat	92
8	P284 Prospective multicenter trial of tigecycline for treatment of central venous catheter (CVC)-related coagulase-negative staphylococcal (CoNS) bacteremia 2009 ·International Journal of Antimicrobial Agents ·D. G. Maki, Arnold Lentnek, (unknown), Joseph A. Paladino, (unknown), Linda L. Jagodzinski, J J Schentag	1
9	Telavancin Versus Vancomycin for the Treatment of Complicated Skin and Skin‐Structure Infections Caused by Gram‐Positive Organisms 2008 ·Clinical Infectious Diseases ·Martín E. Stryjewski, Donald R. Graham, Samuel E. Wilson, William O’Riordan, David M. Young, Arnold Lentnek, (unknown), Vance G. Fowler, Alan R. Hopkins, H. David Friedland, Steven L. Barriere, Michael M. Kitt, G. Ralph Corey, (unknown)	236
10	Safety and efficacy of intravenous tigecycline in treatment of community-acquired pneumonia: results from a double-blind randomized phase 3 comparison study with levofloxacin 2008 ·Diagnostic Microbiology and Infectious Disease ·Carlos Bergallo, Abel Jasovich, (unknown), María Eugenia Oliva, Arnold Lentnek, (unknown), (unknown), Gary Dukart, Angel Cooper, Rajiv Mallick	73
11	Nitazoxanide for the Treatment of Clostridium difficile Colitis 2006 ·Clinical Infectious Diseases ·Daniel M. Musher, Nancy Logan, Richard J. Hamill, Herbert L. DuPont, Arnold Lentnek, Arvind Gupta, Jean François Rossignol	192
12	Reply to Young et al. 2006 ·Clinical Infectious Diseases ·Daniel M. Musher, Nancy Logan, Richard J. Hamill, Herbert L. DuPont, Arnold Lentnek, (unknown), Jean‐François Rossignol	3
13	Efficacy and Safety of Weekly Dalbavancin Therapy for Catheter-Related Bloodstream Infection Caused by Gram-Positive Pathogens 2005 ·Clinical Infectious Diseases ·Issam Raad, Rabih O. Darouiche, José A. Vázquez, Arnold Lentnek, Ray Hachem, Hend Hanna, Beth P. Goldstein, Tim Henkel, Elyse Seltzer	232
14	Evaluation of New Anti-Infective Drugs for the Treatment of Acute Bacterial Meningitis 1992 ·Clinical Infectious Diseases ·George H. McCracken, Merle A. Sande, Arnold Lentnek, Richard J. Whitley, W. Michael Scheid	8
15	Evaluation of New Anti-Infective Drugs for the Treatment of Viral Encephalitis 1992 ·Clinical Infectious Diseases ·Richard J. Whitley, Arnold Lentnek, George H. McCracken, Merle A. Sande, W. Michael Scheid	1
16	Evaluation of New Anti-Infective Drugs for the Treatment of Toxoplasma Encephalitis 1992 ·Clinical Infectious Diseases ·Merle A. Sande, Richard J. Whitley, George H. McCracken, Arnold Lentnek, W. Michael Scheid	2
17	Efficacy of Aztreonam in the Treatment of Skeletal Infections Due to Pseudomonas aeruginosa 1991 ·Clinical Infectious Diseases ·Dennis A. Conrad, (unknown), (unknown), Arnold Lentnek	7
18	Comparative evaluation of nystatin pastille and clotrimazole troche for the treatment of candidal stomatitis in immunocompromised patients. 1990 ·Current Therapeutic Research ·Dennis A. Conrad, Arnold Lentnek	2
19	Efficacy of ceftizoxime administered twice daily in hospitalized patients with respiratory tract infections. 1984 ·PubMed ·Arnold Lentnek, Matthew A. Wikler, (unknown), Claudine Sohn	3
20	Comparative study of ceftizoxime and cefamandole in the treatment of bronchopulmonary infections 1982 ·Journal of Antimicrobial Chemotherapy ·Jack L. LeFrock, (unknown), Arnold Lentnek, K. V. I. Rolston, (unknown), B R Smith, (unknown), Ronald F. Schell, (unknown), (unknown)	5

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact